Centers for Disease Control and Prevention

The Centers for Disease Control and Prevention is presented in Dopesick less through its internal structure than through the evidence and guidance it makes available to the public. Its statistics help show the scale and uneven geography of the opioid crisis; its 2016 prescribing recommendations mark a national response that came late in the epidemic and remained advisory. Across these roles, the agency’s work gives the book tools to examine who was exposed to opioids, who died, and how policy tried to respond.

Public-health evidence and surveillance

The book draws on Centers for Disease Control and Prevention data to place individual deaths within a much larger pattern. A 2015 agency report on heroin-related drug-poisoning deaths recorded 8,257 such deaths between 2000 and 2013; the evidence cited alongside it notes that total drug-overdose deaths reached 43,982 in 2013. The figures do not make any single loss less particular. They establish that the deaths surrounding families in the narrative were part of a broad and accelerating public-health emergency.

Other agency statistics help locate that emergency geographically. Data based on 2015 prescribing rates ranked Martinsville, Virginia, first in the country for opioid prescribing per person and Norton, Virginia, second. The book uses this comparison to show that exceptionally high prescribing was not confined to cities or to places usually imagined as the centers of a drug crisis. Rural communities could occupy the forefront of opioid exposure even as their health-care resources and economic prospects were under pressure.

The author also invokes Centers for Disease Control and Prevention statistics showing higher overdose death rates in rural America. In the book’s argument, prescribing volume and overdose mortality are not interchangeable measures, but together they help trace the crisis across both supply and consequence. The agency’s figures make visible patterns that local anecdotes alone could not establish, while the narrative’s families and communities give those aggregate patterns a human setting.

Prescribing guidance and the timing of intervention

In 2016, the Centers for Disease Control and Prevention issued voluntary guidelines for prescribing opioids for chronic pain. The recommendations strongly urged doctors to limit opioid use in that context. The book emphasizes how late this national guidance arrived: its recommendations echoed warnings that Barbara Van Rooyan had asked the Food and Drug Administration to adopt a decade earlier. The parallel is not that the two interventions were identical, but that a concern voiced years before had taken a long time to appear in a major public-health recommendation.

The guidelines were voluntary, not a blanket prohibition. That distinction matters in a book concerned both with opioid-related harm and with people living in legitimate pain. The author notes that more than half of patients taking OxyContin were still on doses higher than the Centers for Disease Control and Prevention suggested, while some patients whose pain had been stabilized by the medication feared that the pendulum was now swinging too far in the opposite direction. The agency’s recommendations therefore enter a contested clinical landscape: they express an effort to constrain risk, but their existence does not settle how clinicians should respond to every patient or pain condition.

The guidelines also appear alongside a longer institutional delay. The American Medical Association waited two decades before endorsing removal of pain as the fifth vital sign from its standards of care. In this account, the Centers for Disease Control and Prevention’s guidance is one consequential intervention within a wider reconsideration of pain treatment, not a solitary fix for prescribing practices shaped over many years.

Unequal exposure and unequal enforcement

The book uses 2014 Centers for Disease Control and Prevention data to examine racial differences in opioid prescribing. The account reports that doctors prescribed painkillers to people of color at substantially lower rates than to white patients because they were less likely to trust them not to misuse the drugs. Researcher Andrew Kolodny described the resulting pattern as an apparent protective effect of racial stereotyping: by 2014, overdose deaths among young white people had risen to three times their 2002 rate, while the death rate for people of color was relatively unchanged.

That contrast is not presented as evidence of an inherent difference between groups. It exposes how medical judgments about patients could shape access to prescribed opioids and, in turn, form part of the crisis’s unequal consequences. The book sets the data beside the criminal-justice system’s unequal treatment of drug offenders: the largely white group of opioid users could be discussed as a population that could not be arrested out of addiction, while Black and Hispanic people remained heavily represented among federal drug offenders. The agency’s prescribing data thus contribute to an account in which health care and enforcement produce different risks and burdens across racial groups.

What the agency’s role reveals

The Centers for Disease Control and Prevention serves as both a source of measurement and a source of guidance. Its figures help the book connect individual stories to national totals, rural patterns, and differences in prescribing. Its chronic-pain guidelines provide a benchmark against which prescribing could be questioned, even as the text records the limits of voluntary recommendations and the concerns of patients who depend on pain treatment.

The chronology gives these functions a tension. By the time the agency issued its 2016 guidance, the crisis had already produced years of warnings, widespread exposure, and thousands of heroin-related deaths. The book does not claim that one agency or one guideline could reverse those conditions. Instead, it uses the Centers for Disease Control and Prevention’s data and recommendations to clarify the scale of the problem, the unevenness of its effects, and the distance between recognizing a public-health danger and changing the systems that helped shape it.